Sort by
Refine Your Search
-
and tested against the relevant protein as a proof of concept. This is an opportunity to join a vibrant medicinal chemistry research group focussed on developing new technologies for drug discovery. It
-
. Breast cancer is the most common malignancy in the UK, with over 55 000 new diagnoses annually. Surgery (lumpectomy or mastectomy) is the best line of treatment. To enable surgeons to identify the cancer
-
Award Summary 100% fees covered, and a minimum tax-free annual living allowance of £20,835 (2025/26 UKRI rate). Overview The Award This PhD project is a partnership between Scottish Power and
-
2022. The problem? Manually giving well-considered consent to every data use in real time is impossible. The solution? Autonomous agent systems that protect your privacy efficiently, transparently, and
-
(UK home only), a minimum tax-free annual living allowance of £21,805 (2026/27 UKRI rate), and a research training support grant of £20,000. Overview This PhD project is part of the CDT in Process
-
). Additional project costs will also be provided. Overview Additive manufacturing (3D printing) is a digital technology and a key enabler for realising next-generation equipment designs that are less energy
-
Award summary 100% fees (UK home only), a minimum tax-free annual living allowance of £21,805 (2026/27 UKRI rate), and a research training support grant of £20,000. Overview This PhD project is part
-
that can be added to soils – is rapidly gaining attention as a scalable carbon dioxide removal (CDR) and sequestration solution. But what makes biochar and other pyrogenic carbon (PyC) (like charcoal), last
-
Award Summary 100% fees (UK Home only), a minimum tax-free annual living allowance at the 2026/27 UKRI rate (note that the 2025/26 rate is £20,780), and a research training support grant of £20,000
-
pathways. The goal is to design bio-instructive materials that actively direct immune and bone cells toward regeneration. These will be characterised using AFM and rheology, followed by immune–osteogenic co